Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 75

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 75
---
,500. On March 14, 2024, Mr. Raha was granted 64,493 PSUs, which are subject to the achievement of revenue and adjusted EPS targets based on fiscal year 2026 results and relative total stockholder return targets over a three-year measurement period ending December 31, 2026, and 64,494 RSUs, which are subject to time-based vesting requirements (33.3% vesting each year over a three-year period).

50

On February 24, 2025, the Board appointed Mr. Raha to succeed Mr. Diaz as our President and Chief Executive Officer on the Transition Effective Date. In connection with his new appointment, we entered into the Raha Employment Agreement with Mr. Raha setting his annual base salary at $920,000, with a target annual bonus equal to 100% of his annual base salary upon achievement of goals to be established by the CHCC each fiscal year and eligibility to participate in our annual long-term incentive compensation program. The Raha Employment Agreement also provides for a one-time grant of 141,050 RSUs subject to performance-based vesting in four equal installments based upon the achievement of certain stock price targets, provided that no portion of these RSUs will vest earlier than the first anniversary of the Transition Effective Date. Mr. Raha will also be entitled to an additional 2025 equity award grant of RSUs valued at up to $6,000,000 in accordance with our annual equity grant cycle, with such award consisting of (i) 50% RSUs and (ii) 50% PSUs, as determined by the CHCC in its sole discretion.

Mr. Verratti was appointed to the position of President of Myriad Neuroscience on August 1, 2017, and entered into the Company's standard form of employment agreement at that time. Mr. Verratti was also appointed to the position of President of Myriad Autoimmune on May 1, 2020, a position he held until we sold our Autoimmune business on September 13, 2021. Prior to his appointment as Chief Commercial Officer on April 14, 2022, Mr. Verratti also served as President, Mental Health following the sale of the Company's Autoimmune business. Mr. Verratti received a salary of $552,344 for the 2024 fiscal year. His incentive bonus for the 2024 fiscal year was $489,720. On March 14,